Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.

Journal of thrombosis and haemostasis : JTH - 1 Jun 2016

Hoffman M, Chang J-Y, Ezban M, Monroe D M

Abstract excerpt

UNLABELLED: Essentials Disorders of hemostasis can lead to delayed and defective wound healing. In hemophilia B (HB) mice, 7 days of Factor (F)IX or VIIa are needed to normalize wound healing. One dose of a highly active FVIIa variant (DVQ) restored normal wound closure time in HB mice. Coagulation factors with enhanced activity may acquire biological effects not due to hemostasis. SUMMARY: Introduction We have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Topical
Share to Factor IX

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIIa

Share to Hemophilia B

Share to Hemostasis

Share to Recombinant Proteins

Share to Thromboplastin

Share to Wound Healing

Source

Identifiers

PMID: 26952654
DOI: 10.1111/jth.13311

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.PMID 26952654Read ↗

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Semantic proximity Read ↗

Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.Semantic proximity Read ↗

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Semantic proximity Read ↗

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.Semantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.Semantic proximity Read ↗

The Function of extravascular coagulation factor IX in haemostasisSemantic proximity Read ↗

Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.Semantic proximity Read ↗

Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and characterization of the coagulation deficit.Semantic proximity Read ↗

New insights into the biology of tissue factor pathway inhibitor.Semantic proximity Read ↗

Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.Semantic proximity Read ↗

Effect of a truncated mutant factor V on hemostatic function and embryonic development in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.